We did it! In a landmark verdict, the Indian Patent Office rejected Johnson and Johnson’s patent application that would have extended the monopoly on key anti-TB drug #Bedaquiline! @ptisile and I – both of us TB survivors -- had filed pre-grant opposition against the application 
@Ptisile @StopTB @TbDivision @doctorsoumya @WHO Bedaquiline is key anti-TB drug for people with severe forms of TB that has shown to improve cure rates and have lesser side effects. I can't think of a better news ahead of #WorldTBDay2023 !
Thank you for the all wishes! This victory wouldn't have been possible without @MSF_Ind @priyamliz @singh_jyotsna and Roshan.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
